US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER |
| February 17, 2018 | February 2018 Bond Updates |
|
WILMINGTON, Del., Feb. 16, 2018 /PRNewswire/ -- AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved IMFINZI® (durvalumab) for the treatment of patients with unresectable Stage III... |
| View more at: https://www.prnewswire.com/news-releases/us-fda-approves-imfinzi-durvalumab-for-unresectable-stage-iii-non-small-cell-lung-cancer-300600414.html |
| Related News |